info@PremierEndpoint.com (914) 315-9334
Oncology
Improved rPFS for enzalutamide vs. bicalutamide: mCRPC
October 22, 2016

FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer http://finance.yahoo.com/news/fda-approves-supplemental-drug-application-155500472.html U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic […]

Interview with David Esposito of Armune BioScience
October 20, 2016

This is the first post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in development. Here we talk with David Esposito, President and Chief Executive Officer at Armune BioScience, Ann Arbor, Michigan. DAVID ESPOSITO: Armune BioScience is an early stage, medical diagnostics company started in […]